Skip to main content
SpringerLink
Log in

Herzschutz bei Diabetes

Sind manche Antidiabetika besser als andere?

Cardioprotection and diabetes mellitus — which antidiabetic agents seem to do better

  • FORTBILDUNG . SEMINAR
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Aufgrund der bemerkenswerten Datenlage der seit 2015 publizierten großen Outcome-Studien im Bereich des Typ-2-Diabetes mellitus [1, 2] wäre eine (vor-)schnelle Beantwortung der oben formulierten Frage verlockend. Doch ganz so einfach ist es nicht, meint unser Autor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Zinman B et al. EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117–28.

    Article  CAS  Google Scholar 

  2. Marso S et al. LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311–22.

    Article  CAS  Google Scholar 

  3. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–59.

    Article  Google Scholar 

  4. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular out-comes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–72

    Article  Google Scholar 

  5. Nissen SE et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007 Jun 14;356(24):2457–71

    Article  CAS  Google Scholar 

  6. Effect of intensive blood-glucose control with metformin on complications in over-weightpatients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):854–65. Erratum in: Lancet1998 Nov 7;352(9139):1558.

    Article  Google Scholar 

  7. Roumie CL et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med. 2012 Nov 6;157(9):601–10.

    Article  Google Scholar 

  8. Boussageon R, et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med. 2012;9(4):e1001204.

    Article  Google Scholar 

  9. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837–53. Erratum in: Lancet 1999 Aug 14;354(9178):602.

    Article  Google Scholar 

  10. Forst T et al. Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies. Diab Vasc Dis Res. 2013; 10: 302–1

    Article  CAS  Google Scholar 

  11. Roumie CL et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Annals of Internal Medicine (2012; 157: 601–10)

    Article  Google Scholar 

  12. Selvin E, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008; 168: 2070–2080

    Article  Google Scholar 

  13. Simpson SH et al. Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol 2015; 3: 43–51.

    Article  CAS  Google Scholar 

  14. Scirica BM et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013 Oct 3;369(14):1317–26.

    Article  CAS  Google Scholar 

  15. Green JB et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015 Jul 16;373(3):232–42

    Article  CAS  Google Scholar 

  16. Holman RR et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017 Sep 28;377(13):1228–1239.

    Article  CAS  Google Scholar 

  17. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabe-tes. N Engl J Med. 2016 Nov 10;375(19):1834–1844. Epub 2016 Sep 15.

    Article  CAS  Google Scholar 

  18. Kosiborod M et al. Lower Risk of Heart Failure and Death in Patients Initiated on Sodi-um-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodi-um-Glucose Cotransporter-2 Inhibitors). Circulation. 2017 Jul 18;136(3):249–259.

    Article  CAS  Google Scholar 

  19. Haffner SM et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in non diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–34

    Article  CAS  Google Scholar 

  20. Ronco C et al. Cardiorenal syndrome. J Am Coll Cardiol. 2008 Nov 4;52(19):1527–39. Review.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. München-Denning, Cosimastraße 2, D-81927, München, Deutschland

    Marcel Roos (Internist, Diabetologe (BLÄK), Nephrologe, Hypertensiologe (DHL), Diabetologische Schwerpunktpraxis)

Authors
  1. Marcel Roos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcel Roos.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Roos, M. Sind manche Antidiabetika besser als andere?. MMW - Fortschritte der Medizin 160, 65–70 (2018). https://doi.org/10.1007/s15006-018-0386-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-018-0386-3

Keywords

Search

Navigation